Italia markets open in 7 hours 25 minutes

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,7000-0,0900 (-2,37%)
Alla chiusura: 03:59PM EST
3,6530 -0,05 (-1,27%)
Dopo ore: 05:27PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,7900
Aperto3,7873
Denaro3,6500 x 1000
Lettera3,9800 x 1000
Min-Max giorno3,6900 - 3,7800
Intervallo di 52 settimane2,8900 - 11,0000
Volume6.610
Media Volume15.549
Capitalizzazione18,247M
Beta (5 anni mensile)1,72
Rapporto PE (ttm)N/D
EPS (ttm)-0,0790
Prossima data utili27 mar 2023 - 31 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A28,00
  • GlobeNewswire

    Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

    Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across its development pipeline, advancing towards go/no-go decision milestones at each stage to establish prioritization and drive momentumStrategic decision to streamline development programs by discontinuing the Company’s early-stage vaccine programs provides Aeterna Zentaris with an expected extended cas

  • GlobeNewswire

    Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

    Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 1

  • GlobeNewswire

    Aeterna Zentaris Reports Third Quarter 2022 Financial Results

    – Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the third quarter ended Sept